Post on 02-Apr-2018
transcript
7/27/2019 Beximco Pharma Valuation
1/25
7/27/2019 Beximco Pharma Valuation
2/25
About UsSL. NAME ID
01 Mohammad Rabin Islam 16-013
02 Md. Atiar Rahman 16-14103 Md. Sanowar Hossain 16-175
04 Md. Azizul Islam 16-260
05 Ariful Hossain 16-262
06 Md. Mahbubur Rahman Khan 16-263
7/27/2019 Beximco Pharma Valuation
3/25
Our Agenda Company History Overview
Strategic Analysis
Industry AnalysisWACC and Share Price
Ratio Analysis
Conclusion
7/27/2019 Beximco Pharma Valuation
4/25
Year of Establishment :: 1976 Country of Incorporation :: Bangladesh
Commercial Production :: 1980
Status :: Public LimitedAuthorized Capital (Taka) :: 9,100 million
Paid-up Capital (Taka) :: 3,046.3 million
Number of Shareholders :: Around 89,000
Main Country of operation :: Bangladesh
Number of Employees :: 2,670
Company Overview:
7/27/2019 Beximco Pharma Valuation
5/25
Corporate Governance: The Company has a three-tier management structure,
comprising the Board of Directors, the Executive
Committee and the Management Committee. There isalso an Audit Committee, constituted in 2006.
Board Details
1.Executive Committee2.Management Committee
3.Audit Committee
7/27/2019 Beximco Pharma Valuation
6/25
7/27/2019 Beximco Pharma Valuation
7/25
Now Presenting..
Mohammad Rabin Islam 16-013
7/27/2019 Beximco Pharma Valuation
8/25
Strategic Analysis
Generally the companies use StrategicAnalysis as a basis for their businessstrategy.
Beximco Pharma follows costleadership approach as Beximco
Pharmas main focus is on costreduction in every activity in the valuechain.
Beximco Pharma has differentiateditself by offering generic drugs at the
most affordable price.
7/27/2019 Beximco Pharma Valuation
9/25
Industry AnalysisCompetitive force: 1 Rivalry among existing firms
price engages the firms in wars in the industry
Beximco fights against the Square pharma then there
are no destructive price competitions among them By considering Switching Cost the company has been
able to differentiate the products in the market
Beximco pharmaceutical Ltd. has able to fulfill thehuge customer demands and also earn abnormal profit
So there is a good advantage for the company to cutprices to fill capacity
7/27/2019 Beximco Pharma Valuation
10/25
Industry Analysis ContdCompetitive Force 2: Threat of New Entrants
Beximco Pharmaceuticals Ltd is earning abnormal
profit. As we know the potential for earning abnormalprofit attracting new entrants to an industry. BeximcoPharmaceuticals Ltd has already established in themarket by maintaining:
Economy of Scale First Mover Advantage
Access to channels of distribution andrelationships
7/27/2019 Beximco Pharma Valuation
11/25
Md. Atiar Rahman 16-141
Now Presenting..
7/27/2019 Beximco Pharma Valuation
12/25
Industry Analysis ContdCompetitive Force 3: Threat of Substitute Product Relevant substitutes are not necessary for those that
have the same form as the existing products, but thosethat perform the same function.
For example, Beximco Pharma produces differentproducts. Napa is one of them for reducing the fever. Onthe other hand Square pharmaceuticals also produceACE for reducing the fever. But the price of this product
is almost same of these companies. So, customer buyssometimes NAPA and sometimes ACE.
Its a threat for the Beximco Pharmaceuticals Ltd.Having the reputation and goodwill of the company isleading position among the pharmaceutical companies.
7/27/2019 Beximco Pharma Valuation
13/25
Industry Analysis Contd
Competitive Force 4: Bargaining Power of Buyers Price Sensitivity: Buyers are more prices sensitive when the
product is undifferentiated but in the Beximco pharma thereis no undifferentiated products. When the products areundifferentiated there is low switching cost here. Beximco
pharma has so many products such as Napa Extra,Oseltamivir,Decomit, Nitrosol, Bexi gold,Dexiten,Atrizin,NapaDT,Ras,Saritene,Nitaxide, Q-Respria 1, 2 etc all products Priceare fixed. We know that in the field of medicine site buyer feelreluctant to bargain.
Relative Bargaining Power: Having the fixed Price ofBeximco Parmas product so the buyers in the market have noability to bargain. They feel interest to buy on the showing
price.
7/27/2019 Beximco Pharma Valuation
14/25
Industry Analysis Contd
Competitive Force 5: Bargaining Power ofSuppliers Beximco Pharmaceuticals Ltd as supplier has a strong
bargains power in Pharmaceuticals Ltd companies.
Because we have some unique features thus make usunique. We have IV fluid manufacturing plant, MDIplant and Oral solid dosage (OSD) plant.
Beximco Pharmaceuticals Ltd have supported byownsbackward and forward integration. Because Beximcopharma have a own paper printing machine and plasticmachine. The cover of the medicine is made by theBeximco plastic industries LTD. So it was backward
integration ofBeximco pharma.
7/27/2019 Beximco Pharma Valuation
15/25
Now Presenting..
Md. Mahbubur Rahman Khan 16-263
7/27/2019 Beximco Pharma Valuation
16/25
7/27/2019 Beximco Pharma Valuation
17/25
WACC and Share Price Contd
Enterprise value 37,796,087,803.52
Cash 518,768,296Interest-bearing debt 3,896,034,840Equity value 34,418,821,259.52
Value per share 136.71
Current Forecast Price is Tk.136.71 and Current Market Price is Tk.56.71So, The Share Price of Beximco Pharma is Undervalued by Tk.80
7/27/2019 Beximco Pharma Valuation
18/25
Ariful Hossain 16-262
Now Presenting..
7/27/2019 Beximco Pharma Valuation
19/25
Ratio AnalysisInvestment Valuation Ratios:
Dividend per share =goutstandinsharesofNumber
dividend
Interpretation: Only in the year 2008 the Dividend Per Sharewas the highest because of the high (30%) dividend in that year.Then, although Dividend Per Share dropped in the next year
(15%), it was increasing from year 2009 to 2011.
7/27/2019 Beximco Pharma Valuation
20/25
Ratio Analysis ContdProfitability Ratios:
Net Profit Margin(%) =Revenue
incomeNet
Interpretation: There is a steady growth in the net profitmargin as the companys Net Income and Sales Revenue are
increasing gracefully every year.
7/27/2019 Beximco Pharma Valuation
21/25
Now Presenting..
Md. Azizul Islam 16-260
7/27/2019 Beximco Pharma Valuation
22/25
Ratio Analysis ContdLiquidity And Solvency Ratios:
Current Ratio =sLiabilitieCurrent
setsCurrent As
Interpretation: From 2008 the current ratios were decreased but in 2009 it wasincreased .Because the current assets were decreased in 2008 and 2010 and liabilities
were increased so that the current ratios were decreased. But in 2009 and 2011 the ratioswere increased due to the increasing in current asset. So increasing in current assets
help to meet up the current liabilities.
7/27/2019 Beximco Pharma Valuation
23/25
Ratio Analysis Contd
Management Efficiency Ratios:
Working capital turnover =capitalworkingAverage
Revenue
Interpretation: It shows how effectively a company is using its working capital togenerate sales. In this case Beximco Pharmas Working Capital Turnover is increasinggently over the five years indicating that it is quite efficient in manipulating its Working
Capital to generate Revenue.
7/27/2019 Beximco Pharma Valuation
24/25
Conclusion Beximco Pharmaceuticals Ltd (BPL) is a leading
manufacturer of pharmaceutical formulations and ActivePharmaceutical Ingredients (APIs) in Bangladesh.
The company is consistently building upon its portfolio andcurrently producing more than 400 products in differentdosage
With decades of contract manufacturing experience with
global MNCs, skilled manpower and proven formulationcapabilities, the company has been building a visible andgrowing presence across the continents offering high return
7/27/2019 Beximco Pharma Valuation
25/25
QUERY SESSION.
?!?!?..